CurrentBlue Cross Blue Shield - MassachusettsPolicy BCBSA 7.01.177

Processed nerve allografts and synthetic nerve conduits for peripheral nerve gap repair

Defines medical necessity and investigational indications for use of processed nerve allografts and synthetic nerve conduits to repair peripheral nerve gaps in Commercial and Medicare members, including contraindications and prior authorization requirements. Specifies gap-length–based criteria and limitations (e.g., maximum allograft length 70 mm) and scenarios where conduits are medically necessary.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyProcessed nerve allografts and synthetic nerve conduits for peripheral nerve gap repair

Policy CodePolicy BCBSA 7.01.177

Change TypeNew medical policy

Effective DateAug 1, 2025

Next Review Date

Key ActionPrecertification/preauthorization is required for all products if the procedure is performed inpatient; document that direct primary (tensionless) repair is not feasible when requesting processed nerve allograft and document allograft availability if using a synthetic conduit.

POLICY UPDATE CHANGES

New medical policy describing medically necessary and investigational indications.

70Max allograft length (mm)

15-25Digital nerve conduit gap (mm)

≤6Major nerve conduit threshold (mm)

2RCTs cited

Coverage Summary

Scope: Defines medical necessity and investigational indications for use of processed nerve allografts and synthetic nerve conduits to repair peripheral nerve gaps in Commercial and Medicare members, including contraindications and prior authorization requirements. Coverage stance: mixed — some indications are medically necessary while others are investigational. Subject: Processed nerve allografts and synthetic nerve conduits for peripheral nerve gap repair. Policy number: BCBSA 7.01.177. Key thresholds: maximum processed nerve allograft length 70 mm, and conduit gap thresholds for digital nerves 15-25 mm (or <15 mm), and major nerve small gaps ≤ 6 mm when allograft is not available. Effective date: 2025-08-01.

Thresholds

Maximum processed nerve allograft length70 mm

Digital nerve gap where conduit acceptable if allograft unavailable15-25 mm

Digital nerve gap where conduit acceptable< 15 mm

Major nerve small gap threshold for conduit when allograft unavailable≤ 6 mm

Medical Necessity Criteria

Processed Nerve Allograft — Medically Necessary

Covered when ALL of the following are met:

Used for repair and closure of peripheral nerve gaps up to 70 mmMaximum processed nerve allograft length 70 mm
Direct primary (tensionless) repair is not feasible
Contraindication: Procedure is not performed in a surgical field with active infection
Contraindication — active infection

ref_ID_or_label_that_does_not_matter_to_parser_but_must_equal_ref_used_above_if_applicable_or_left_blank_ref_must_equal_b1_0_or_exact_ref_provided_else_echoed_below_ref_b1_0_was_provided_in_prompt_but_field_spec_says_echo_ref_exactly_below_ref_b1_0_must_be_present_and_exactly_match_the_block_ref_in_the_PROMPT_ref_b1_0_echoed_below_but_kept_short_for_parser_compatibility_b1_0_but_must_be_valid_json_key_is_not_allowed_here_so_included_in_next_field_is_ref

ref': 'b1_0'

Synthetic Nerve Conduit — Medically Necessary Scenarios

Synthetic nerve conduits are considered MEDICALLY NECESSARY in ANY of the following scenarios:

Repair of digital nerve injuries with gaps 15-25 mm, where allograft nerve is not availableDigital nerve gap where conduit acceptable if allograft unavailable 15-25 mm
Repair of digital nerve injuries with gaps <15 mmDigital nerve gap where conduit acceptable <15 mm
Repair of major nerves with small gaps not exceeding 6 mm, where allograft nerve is not availableMajor nerve small gap threshold for conduit ≤6 mm
In the context of conduit-assisted repair as a technique for tension-relief at the peripheral nerve repair site

All Other Uses

All Other Uses: All other uses of processed nerve allografts and synthetic nerve conduits for individuals with peripheral nerve gaps are considered INVESTIGATIONAL/NOT COVERED

Provider Actions & Billing Impact

Prior Authorization

Precertification/Preauthorization required for inpatient procedures

Precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient.

Documentation Required

Document feasibility of direct repair

Provider must document that direct primary (tensionless) repair is not feasible when requesting processed nerve allograft for gaps up to 70 mm.

Documentation Required

Document allograft availability for conduit use

When synthetic conduit is used for digital nerve gaps 15-25 mm or major nerve gaps ≤6 mm, documentation must show that allograft nerve is not available (where applicable) if that is the basis for conduit use.

Denial Risk

Contraindication — active infection

Claims may be denied if the procedure is performed in a surgical field with active infection; both processed nerve allograft and synthetic conduit repair are contraindicated in the presence of active infection.

Denial Risk

Contraindication — allergy to conduit materials

Synthetic conduits are contraindicated and may be denied for members with a history of allergic reaction or sensitivity to any component of the synthetic conduit (examples: bovine, porcine, chondroitin).

Background & Evidence

Processed nerve allografts (allografts) and synthetic nerve conduits are alternatives to autograft for bridging peripheral nerve discontinuities to avoid donor-site morbidity. Autograft is standard for larger sensory, motor, or mixed nerves when sufficient donor material exists. Evidence is primarily in digital and upper extremity nerve injuries; comparative evidence to autograft is limited.

Evidence Type	Summary
RCTs (allograft vs NeuraGen)	2 RCTs reported greater return of protective sensation (static 2‑point discrimination) with allograft in some measures but mixed results across other outcomes (no consistent differences in moving 2‑point discrimination, Semmes‑Weinstein monofilament, or DASH); trial limitations included high loss to follow‑up and other methodological issues.
Meta-analyses	Meta-analyses show heterogeneous results: one found comparable pooled rates of S2PD and MZPD across interventions with extreme heterogeneity; another found meaningful recovery higher with allograft/autograft versus synthetic conduits.

Direct primary repair: Tensionless end-to-end coaptation/neurorrhaphy of a transected nerve when gap size permits.

Processed nerve allograft: Decellularized human donor nerve grafts processed to reduce immunogenicity and provide a scaffold for nerve regeneration.